NASDAQ: BYSI - BeyondSpring Inc.

Yield per half year: -31.57%
Dividend yield: 0.00%
Sector: Healthcare

Share chart BeyondSpring Inc.

Extended chart Simple chart
Financial Markets by TradingView

About BeyondSpring Inc.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer.

more details
It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2017-03-09
ISIN KYG108301006
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://beyondspringpharma.com
Цена ао 3.61
Change price per day: -2.75% (1.6607)
Change price per week: +1.57% (1.59)
Change price per month: -14.55% (1.89)
Change price per 3 month: -26.59% (2.2)
Change price per half year: -31.57% (2.36)
Change price per year: +79.44% (0.9)
Change price per 3 year: -64.19% (4.51)
Change price per 5 year: -88.9% (14.55)
Change price per 10 year: 0% (1.615)
Change price per year to date: -12.7% (1.85)
All parameters

Underestimation

Title Value Grade
P/S 19.87 1
P/BV -1.48 0
P/E 0 0
EV/EBITDA -0.9219 0
Total: 3.63

Efficiency

Title Value Grade
ROA, % -84.75 0
ROE, % 78.44 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.1751 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 872.78 10
Yield Ebitda, % -46.15 0
Yield EPS, % -65.21 0
Total: 2
More

Institutions Volume Share, %
Decheng Capital Management III (Cayman), LLC 4958143 12.74
Decheng Capital LLC 4958143 12.74
Blackrock Inc. 224285 0.58
Group One Trading, L.P. 56986 0.15
Capstone Capital Wealth Advisors 50500 0.13
Acadian Asset Management. LLC 34799 0.09
State Street Corporation 32200 0.08
Tanaka Capital Management Inc 29473 0.08
Geode Capital Management, LLC 20183 0.05
Northern Trust Corporation 18565 0.05



Head Job title Payment Year of birth
Dr. Lan Huang Ph.D. Co-Founder, Chairman & CEO N/A 1971 (54 years)
Mr. Linqing Jia Co-Founder N/A
Stephen Kilmer Head of Investor Relations N/A
Mr. Gregg Russo Senior Vice President of Human Resources N/A
Dr. June Lu Ph.D. Chief Scientific Officer N/A

Address: United States, New York. NY, 28 Liberty Street - open in Google maps, open in Yandex maps
Website: https://beyondspringpharma.com